Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.67 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.70 per share a year ago.

Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $65.00. The ...

Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials, the fifth type of cancer the drug has been shown to treat.

Bristol Myers Squibb posted Q4 revenue of $12.34B, beating the consensus, with an 8% YoY increase driven by Growth Portfolio and Eliquis. Adjusted EPS was $1.67, topping the $1.46 consensus but ...

Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference over to ...

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report).

The 2025 forecast reflects a revenue hit of about 18% to 20% to the company's legacy portfolio from the near-term effects of generics on cancer drugs Revlimid, Pomalyst, Sprycel and Apraxane. The ...

Shares in Bristol-Myers Squibb traded about 2.7% lower Thursday after the drug maker gave 2025 guidance that undershot expectations. Bristol expects sales of about $45.5 billion in 2025 ...